PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 26, 2025NEJM Evidence0 citations

Biology-Directed Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements

View Full Paper
VOVivian G. OehlerRWRoland B. Walter

Key Points

  • Approximately 20 unique fgfr1 rearrangements cause uncontrolled cellular proliferation, revealing a complex malignancy landscape.
  • Common rearrangement partners include ZMYM2 and BCR, affecting treatment strategies for these neoplasms.
  • Insights into fgfr1 biology provide avenues for biology-directed therapies, potentially improving patient outcomes.
  • Research emphasizes the significance of understanding fgfr1-driven mechanisms in myeloid/lymphoid neoplasms for therapy development.

Abstract

Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangements (MLN-FGFR1) are rare. Sharing constitutive FGFR1 activation as the driver of uncontrolled cellular proliferation, these malignancies are molecularly diverse, with approximately 20 known rearrangement partners identified to date (ZMYM2 and BCR being the most common).1,2

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Oehler et al. (2025) studied this question.

synapsesocial.com/papers/68af620aad7bf08b1eae3132https://doi.org/10.1056/evide2500196
Ask AI
Helpful
Bookmark
Share
View Full Paper